Skip to main content

Table 3 Relative changes in the expression of gene signatures in response to the 2-week AI treatment of the HER2− and HER2+ tumours.

From: Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients

Module nameHER2-negativeHER2-positiveSignificance of the difference between two changes in expression (HER2−vs HER2+)
%Δ of geometric mean of intensities of a module of pre- and post-treatment2-sided unadjusted p value of paired t testGeometric mean of intensities of a module of pre- and post-treatmentUnadjusted p value of paired t test
ESR1− 23.061.54E−0218.286.23E−019.18E−03
ERGs-GS− 30.798.58E−14− 21.962.85E−035.81E−02
DiLeoRBloss-GS− 27.619.81E−10− 30.641.41E−035.43E−01
JClinInvest2007RBloss-GS− 26.115.47E−10− 29.451.78E−034.72E−01
CIN70-GS− 25.923.26E−10− 28.691.81E−035.40E−01
E2F4activation-GS− 25.264.54E−09− 30.075.02E−033.13E−01
GGI-GS− 23.671.78E−09− 27.851.19E−033.40E−01
ERTarget27-GS− 17.801.32E−15− 11.413.32E−021.71E−02
E2FmotifCellCycleAssociated-GS− 16.755.71E−09− 21.722.00E−031.31E−01
E2Factivation-GS− 14.452.25E−07− 18.201.93E−022.62E−01
AURKA-GS− 13.911.08E−07− 15.453.94E−036.10E−01
Gene70-GS− 9.371.97E−07− 12.346.76E−031.98E−01
SET-GS− 9.341.55E−05− 2.085.69E−018.73E−03
PTEN-GS− 7.551.44E−06− 8.813.62E−025.38E−01
ESR1.2-GS− 5.823.01E−04− 0.468.49E−011.10E−02
ESR1.1-GS− 5.402.99E−030.299.29E−011.50E−02
MYC-GS− 4.361.98E−04− 3.542.24E−016.02E−01
IGF1-GS− 4.154.59E−04− 4.077.76E−029.58E−01
VEGF-GS− 3.853.33E−02− 0.219.48E−011.09E−01
GDNF-GS− 3.411.40E−01− 5.234.25E−015.71E−01
obesity-GS− 3.082.40E−02− 1.725.64E−014.55E−01
E2F3-GS− 2.895.01E−05− 3.792.62E−023.45E−01
PI3K-GS− 1.803.19E−03− 3.116.69E−021.23E−01
SRC-GS− 1.692.83E−01− 1.626.46E−019.74E−01
AKT/mTOR-GS− 1.624.57E−02− 1.953.31E−017.51E−01
RAS-GS− 1.471.93E−01− 0.478.51E−015.04E−01
BetaCatenin-GS− 1.283.83E−010.049.91E−015.07E−01
WntTarget34-GS− 0.308.90E−01− 2.566.50E−014.28E−01
ERBB2-GS0.278.88E−01− 0.888.60E−016.55E−01
PIK3CA-GS0.397.20E−011.773.99E−013.42E−01
STAT1-GS0.798.27E−01− 7.732.98E−016.99E−02
CASP3-GS1.375.57E−01− 1.188.48E−013.82E−01
Bcell-GS1.716.92E−01− 7.383.51E−017.71E−02
MacTh1-GS2.724.94E−010.209.79E−016.38E−01
Tcell-GS2.835.38E−01− 6.134.73E−011.12E−01
Inflammatory-GS2.864.92E−01− 4.805.15E−011.55E−01
Immune.1-GS3.075.24E−01− 5.346.10E−011.49E−01
MAPK-GS3.216.59E−031.945.02E−014.22E−01
Stroma.2.PLAU-GS6.574.65E−024.545.14E−016.34E−01
Stroma.1-GS20.711.17E−0221.871.61E−019.18E−01
TP53-GS29.906.45E−1029.385.59E−039.44E−01
PAGs− 4.406.44E−06− 6.232.06E−021.37E−01
  1. Significant difference test of the changes between HER2− and HER2+ tumours. The increase of TP53-GS score after AI treatment is associated with the TP53 wild-type status